glp 1 and gip receptor agonist New strategies for the treatment of obesity metabolic dysfunctions LY3437943, a novel triple glucagon,

Results In total, 204 cases of SSIBs associated with GLP-1RAs, including semaglutide, liraglutide, dulaglutide, exenatide, and albiglutide, were identified in the FAERS database

The World Obesity Atlas 2024 reports over 1.5 billion projected cases by 2035, highlighting its growing threat among pediatric and adult populations globally

But theres a tradeoff

| 10 comments on LinkedIn

In this Review, the authors discuss the potential effects of GLP-1 receptor agonists on the incidence, disease activity and progression of various forms of arthritis, as well as practical considerations for their use in this context.

FDA is acknowledging that the drugs dont have the same risk seen with older weight-loss medicines